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Abstract
Introduction: EBUS is a well established minimally invasive diagnostic tool for mediastinal and hilar lymphadenopathy. The novel 
ViziShot Flex 19G needle (Olympus Respiratory America, Redmond, WA, USA) was introduced in 2015 in order to improve loaded 
scope flexion and to obtain larger tissue samples for analysis.
The aims of this study were to assess diagnostic yield of Flex 19G needles and to present endoscopist’s feedback about the 
endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).
Material and methods: The Flex 19G needles were used in patients with hilar and/or mediastinal adenopathy in two Polish 
pulmonology centers. Cytology smears and cell blocks (CB) were prepared. The prospective analysis was performed due to 
collected data.
Results: Twenty two selected patients with confirmed adenopathy on chest-CT (mean age 58 ± 12) underwent EBUS-TBNA 
with use of Flex 19G needles. All procedures occurred to be diagnostic for smears (yield 100%). The malignancy was found in 15 
cases (68.2%), and benign adenopathy in 7 (31.8%). In 12 of 14 cases of lung cancer (yield 85.7%) CB were diagnostic for immu-
nohistochemical and molecular staining. After puncturing nodes, especially in hilar position not extensive bleeding was observed. 
Comparing to standard 21/22G EBUS-TBNA endoscopists underlined better flexion of loaded scope and sample adequacy and 
found non-significant differences in another biopsy details.
Conclusions: The first Polish experience with use of Flex 19G EBUS-TBNA needle occurs to be similar in performance with 
standard technique with use of 22/21G needles and presents high diagnostic yield for lung cancer diagnostics, especially when 
preparing CB. A safety profile of the biopsy is acceptable.
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Introduction
The role of the Endobronchial Ultrasound- 
-Guided Transbronchial Needle Aspiration 
(EBUS-TBNA) combined with Endoscopic Ultra-
sonography-Guided Fine Needle Aspiration using 
EBUS scope (EUS-B-FNA) or EUS scope is a well 
established and recommended method as the 
first step towards minimally invasive lung cancer 
staging [1]. EBUS-TBNA is also successfully per-
formed for diagnostic purposes in patients with 
paratracheal and peribronchial tumours [2, 3]. 
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Figure 1. ViziShot 19G Flex needle (Olympus Respiratory America, 
Redmond, WA, USA)
There is quite a lot of data presenting the 
usefulness of the EBUS-TBNA for diagnosing 
patients with benign mediastinal and/or hilar 
lymphadenopathy, especially those suspected of 
sarcoidosis [4]. The area visualised with the EBUS 
scope includes the upper and lower para- and 
retrotracheal, subcarinal and hilar regions. Whe-
reas the only limitation of the ultrasonographic 
visualisation is the outer diameter of the scope, in 
some cases its flexibility decreased by introducing 
TBNA needle into the working channel reduces 
the bioptic area. 
The novel first generation of Flex 19G needle 
(Olympus Respiratory America, Redmond, WA, 
USA) for the EBUS-TBNA use was developed and 
brought to market in 2015. The main advantages 
of the needle claimed by the manufacturer are as 
follows: improved flexibility (from 45° maximal 
flex for scope loaded with standard 21G needle 
to 84° while using Flex 19G needle) (Fig. 1), en-
larged inner lumen with the same outer diameter 
(1.9 mm) for obtaining bigger tissue samples and 
improved echogenicity of the needle for better 
visualisation on ultrasound image. 
In the current paper we presented our initial 
experience of the first generation of Flex 19G 
EBUS-TBNA needle. The aim of our work was to 
assess diagnostic yield and to report complications 
associated while using the tool and to present 
subjective endoscopist’s feedback after its use.
Material and methods
The Flex 19G needle was used for EBUS-TBNA 
in 22 selected patients with enlarged hilar or 
mediastinal lymph nodes on CT scans for sta-
ging and diagnosis of lung cancer and for other 
benign lymphadenopathies. The procedure was 
performed by three experienced endoscopists in 
two Polish pulmonology centers. The Olympus 
EBUS scope (BF-UC180F) with 2.2 mm working 
channel diameter was used. After signing in-
formed consent, all patients underwent EBUS 
under mild conscious sedation with the use of 
midazolam (2–5 mg) and fentanyl (0.025–0.1 mg) 
administered intravenously. Pulsoxymetric me-
asurement for patients’ monitoring was manda-
tory, and oxygen supplementation provided when 
necessary.  
EBUS-TBNA was performed with 2 to 3 ne-
edle passes in at least 2 selected areas. For cyto-
logical assessment smears and cell blocks (CB), 
when malignancy was suspected were prepared. 
After the procedure, both sampled areas (nodal 
stations or tumour) and endoscopist’s feedback 
were noted. Lymph node stations were examined 
in accordance to the lymph node map introduced 
by the International Association for the Study 
of Lung Cancer (IASLC) [5]. Endoscopists were 
asked to fill the questionnaire after finishing the 
procedure. Absolute and relative (comparing with 
standard 21/22G EBUS-TBNA) performance was 
assessed using the questionnaire. Endoscopists 
also answered questions about possible disadvan-
tages of the new needle as shown in Table 1. Phy-
sician’s feedback was referred to flexibility of the 
loaded scope, facility of puncture of the targeted 
area, quality of the needle visualisation in the 
ultrasound image and the quality and amount of 
the obtained tissue for preparing smears. 
Biopsies were assessed by experienced patho-
logists in both hospitals for being diagnostic, and 
if so, for final diagnosis. In case of non-diagnostic 
biopsy, other invasive procedures such as media-
stinoscopy or systematic lymph node dissection 
during lung resection were planned to establish 
final diagnosis. 
Results
Endoscopic procedures were performed in 
October and November 2015 in  Endoscopy Units 
of Pulmonary Hospital in Zakopane (16 patients) 
and John Paul II Hospital in Cracow (6 patients). 
Twenty two selected patients with mediastinal 
and/or hilar lymphadenopathy underwent EBUS-
-TBNA with Flex 19G needle. The examined group 
consisted of 15 (68.2%) men and 7 (31.8%) wo-
men, aged between 32 and 80, mean 58 ± 12 years. 
In 22 patients, 48 selected areas (nodal stations 
or tumours) were biopsied as shown in Table 2. 
The final diagnosis was established by EBUS-TB-
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Table 2. Baseline characteristics
Total (n) 22
Gender  
Male 15 (68.2%)
Female 7 (31.8%)
Age (years) 58 ± 12
Final diagnosis  
Sarcoidosis 4 (18.2%)
Reactive LN 3 (13.6%)
Lung cancer 14 (63.6%)
Adenocarcinoma 5 (22.7%)
Squamous cell carcinoma 4 (18.2%)
Small cell lung cancer 4 (18.2%)
Non-small cell lung cancer 1 (4.5%)
Clear cell adenocarcinoma 1 (4.5%)
Lymph nodes biopsied 48
4R 7
4L 6
7 15
10R 4
10L 2
11R 3
11L 4
Tumor 7
Table 3.  Diagnostic yield of smears and cell blocks (CB)
Final diagnosis Smears n = 22 CB n = 15
22/22 (100%) 13/15 (86.7%)
Sarcoidosis 4/4 (100%) –
Reactive LN 3/3 (100%) –
Lung cancer 14/14 (100%) 12/14 (85.7%)
Clear cell adenocarcinoma 1/1 (100%) 1/1 (100%)
CB — cell blocks
Table 1. Results of the questionaire filled by bronchoscopists after each procedure
Abslute performance Relative performance
Unacceptable Acceptable Worse Comparable Better
Did the device penetrate the target? 1 (4.5%) 21 (95.5%)  – 19 (86.4%) 3 (13.6%)
Did the device collect adequate samples? – 22 (100%)  – 2 (9.1%) 20 (90.9%)
Was the device visible during sampling?  – 22 (100%)  – 20 (90.9%) 2 (9.1%)
Overall impression of performance  – 22 (100%)  – 16 (72.7%) 6 (27.3%)
  Yes No
Did the needle become ‘bent’ or ‘curved’?  – 22
Did the needle become excessively curved?  – 22
Did the needle become noticeably dull?  – 22
Did the needle ever snag and/or penetrate the sheath?  – 22
NA with the use of the Flex 19G needles in all 
cases. There were 7 benign lymphadenopaties 
(4 sarcoidosis and 3 reactive lymph nodes). Ma-
lignancy was found in 15 cases (14 primary lung 
cancers and 1 metastatic clear cell cancer of the 
kidney). If needed, tissue material obtained by 
needle biopsy was adequate for immunocytoche-
mical (IHC) staining and molecular genotyping 
(EGFR mutation testing). Smears were prepared 
in all 22 patients and all of them were found to 
be diagnostic (yield 100%).
Cell blocks (CB) were prepared in 15 patients 
suspected of malignancy and were diagnostic in 
13 of them (86.7%) (Table 3).
 As shown in Table 1, absolute performance 
was acceptable regarding penetration of the target 
(95.5%), collecting adequate sample (100%), visi-
bility of the needle in ultrasonography (100%) and 
overall impression of the procedure (100%). Relati-
ve performance was assessed as comparable in the 
area of target penetration (86.4%), needle visibility 
(90.9%) and overall impression of the procedure 
(72.7%); and was found to be better in obtaining 
adequate samples for preparing smears (90.9%). 
No device dependent complications were reported.
Improved flexibility of the loaded scope me-
asured in our sites was about 21 degrees (from 
57° while using standard 22G needle to 78° with 
new device) (Figs 2, 3).
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Figure 2. EBUS scope loaded with 22G needle
Figure 3. EBUS scope loaded with ViziShot 19G Flex needle
Figure 4. EBUS-TBNA with ViziShot 19G Flex (lymph node 4R)
No severe complications were observed except 
for the subject who presented bleeding after biopsy 
of the right hilar nodes, controlled with cooled saline. 
Discussion
In the first Polish experience, EBUS-TBNA 
with the use of the Flex 19G needles showed 
very high diagnostic yield for malignancy and 
sarcoidosis. But the small number of selected 
patients must be underlined regarding reported 
in the literature diagnostic yield of this procedure 
in lung cancer staging — 89%, and in mediastinal 
lymphadenopathy — 92% [6, 7]. 
The Canadian experience of the device also 
suggests high diagnostic yield in different lym-
phadenopathies [8]. 
The endoscopist’s feedback shown in our 
work corresponds with the results presented by 
Sczaniecka et al. [9] at the European Respiratory 
Society Congress in London (September 2016). 
The tissue sample obtained with the needle 
occurred to be adequate for cytological, IHC and 
molecular (EGFR) lung cancer typing, which is 
in accordance with the literature on the topic 
[10–12]. The quality of CB samples are highly 
promising especially for ALK, ROS1 and PD-L1 
typing, when bigger samples are needed. A com-
plication rate observed in our study was compa-
rable with the standard EBUS-TBNA [1, 2, 6–8]. 
Conclusions
In our experience, Flex 19G EBUS-TBNA 
needle occurs to be similar in performance to 
standard technique using 22/21G needles, and 
presents high diagnostic yield for lung cancer 
diagnostics, especially for preparing CB. A signi-
ficantly better flexion of the loaded scope allows 
the access for the bigger bioptic area, hence better 
sample adequacy can be achieved. A safety profile 
of the biopsy is acceptable.  
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